Trials / Recruiting
RecruitingNCT06055361
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of BxC-I17e Administered Subcutaneously in Patients With Moderate to Severe Atopic Dermatitis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Brexogen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BxC-I17e (primed iMSC derived Extracellular vesicles(EV)) | Pharmaceutical form : solution for injection |
| DRUG | Placebo | Pharmaceutical form : solution for injection |
Timeline
- Start date
- 2023-04-18
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2023-09-26
- Last updated
- 2025-09-19
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06055361. Inclusion in this directory is not an endorsement.